Clinical features and prognostic analysis of mantle cell lymphoma.
- Author:
Wei-ying BAO
1
;
Yan WANG
;
Xi-mei HU
;
Jun-min LI
;
Zhi-xiang SHEN
;
Wei-li ZHAO
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; therapeutic use; Female; Humans; Lymphoma, Mantle-Cell; diagnosis; drug therapy; Male; Middle Aged; Prognosis; Retrospective Studies; Rituximab
- From: Chinese Journal of Hematology 2012;33(10):814-818
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the clinical features, therapeutic effects, survival time and prognostic factors of patents with mantle cell lymphoma (MCL).
METHODSClinical data of 47 MCL patients admitted from January 2002 to December 2011 were retrospectively analyzed.
RESULTSOf all patients, median age was 58 year-old and male to female ratio was 3.3:1. Forty-two cases (89.4%) were in Ann Arbor stage III-IV, 13 cases (27.7%) with bone marrow involvement, 6 cases (12.8%) with lymphocytosis, 18 cases (38.3%) with elevated LDH, and 28 cases (59.6%) with elevated β(2)-MG. Age, bone marrow involvement, increased LDH level and treatment without rituximab were poor prognostic factors. The efficiency and complete remission rate of rituximab combined with chemotherapy were 91.4% and 48.6%, which were superior to those of CHOP regimen (41.7% and 16.7%). As compared to CHOP regimen, rituximab combined with chemotherapy induced longer progression-free survival and overall survival.
CONCLUSIONMost patients with MCL were older adults with a male predominance and usually had bone marrow involvement and poor prognosis. Rituximab combined with chemotherapy could significantly improve patient outcome.
